S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.33 (+0.51%)
MSFT   166.72 (+0.62%)
AMZN   1,885.01 (-0.13%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.44 (-1.32%)
GE   11.79 (+3.70%)
TSLA   572.02 (+0.43%)
AMD   51.71 (+0.54%)
T   38.64 (-1.05%)
ACB   2.07 (+1.47%)
NFLX   349.60 (+7.24%)
DIS   142.20 (-1.26%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.33 (+0.51%)
MSFT   166.72 (+0.62%)
AMZN   1,885.01 (-0.13%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.44 (-1.32%)
GE   11.79 (+3.70%)
TSLA   572.02 (+0.43%)
AMD   51.71 (+0.54%)
T   38.64 (-1.05%)
ACB   2.07 (+1.47%)
NFLX   349.60 (+7.24%)
DIS   142.20 (-1.26%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.33 (+0.51%)
MSFT   166.72 (+0.62%)
AMZN   1,885.01 (-0.13%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.44 (-1.32%)
GE   11.79 (+3.70%)
TSLA   572.02 (+0.43%)
AMD   51.71 (+0.54%)
T   38.64 (-1.05%)
ACB   2.07 (+1.47%)
NFLX   349.60 (+7.24%)
DIS   142.20 (-1.26%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.33 (+0.51%)
MSFT   166.72 (+0.62%)
AMZN   1,885.01 (-0.13%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.44 (-1.32%)
GE   11.79 (+3.70%)
TSLA   572.02 (+0.43%)
AMD   51.71 (+0.54%)
T   38.64 (-1.05%)
ACB   2.07 (+1.47%)
NFLX   349.60 (+7.24%)
DIS   142.20 (-1.26%)
Log in
(Ad)
Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

LON:AGY - Allergy Therapeutics Share Price, Forecast & News

GBX 11.25
0.00 (0.00 %)
(As of 01/23/2020 04:00 PM ET)
Today's Range
11
Now: GBX 11.25
11.37
50-Day Range
10.10
MA: GBX 10.69
11.80
52-Week Range
8
Now: GBX 11.25
15.70
Volume196,365 shs
Average Volume167,682 shs
Market Capitalization£71.57 million
P/E Ratio22.50
Dividend YieldN/A
BetaN/A
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1903-844700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£73.72 million
Cash FlowGBX 4.26 per share
Book ValueGBX 5.90 per share

Profitability

Miscellaneous

Employees500
Market Cap£71.57 million
Next Earnings Date3/4/2020 (Estimated)
OptionableNot Optionable

Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

Allergy Therapeutics (LON:AGY) Frequently Asked Questions

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

When is Allergy Therapeutics' next earnings date?

Allergy Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Allergy Therapeutics.

What price target have analysts set for AGY?

1 equities research analysts have issued 1 year price targets for Allergy Therapeutics' shares. Their forecasts range from GBX 35 to GBX 40. On average, they anticipate Allergy Therapeutics' share price to reach GBX 37.50 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for Allergy Therapeutics.

What is the consensus analysts' recommendation for Allergy Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergy Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergy Therapeutics.

Has Allergy Therapeutics been receiving favorable news coverage?

Media coverage about AGY stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergy Therapeutics earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the stock's share price in the near term. View News Stories for Allergy Therapeutics.

Who are some of Allergy Therapeutics' key competitors?

What other stocks do shareholders of Allergy Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergy Therapeutics investors own include Relypsa (RLYP), Repros Therapeutics (RPRX), Spectrum Pharmaceuticals (SPPI), Verastem (VSTM), Berkeley Energia (BKY), Burford Capital (BUR), Dechra Pharmaceuticals (DPH), Flowtech Fluidpower (FLO), Shanta Gold (SHG) and Sosandar (SOS).

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the folowing people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 55)
  • Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 54)
  • Ms. Beverly Lees, Group Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 11.25.

How big of a company is Allergy Therapeutics?

Allergy Therapeutics has a market capitalization of £71.57 million and generates £73.72 million in revenue each year. Allergy Therapeutics employs 500 workers across the globe.View Additional Information About Allergy Therapeutics.

What is Allergy Therapeutics' official website?

The official website for Allergy Therapeutics is http://www.allergytherapeutics.com/.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.


MarketBeat Community Rating for Allergy Therapeutics (LON AGY)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  352 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  544
MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote "Outperform" if you believe AGY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel